Alheli Arce Gastelum, MD
Internal Medicine · Fresno
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
- Since medical school
- 10 years
- Graduated 2016
Offices
2 locations · Clinica Sierra Vista · 180 clinicians in this group
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Gastelum’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A174340 · Current
Licensed to practise in California · since 2021 · expires 2027-08-31 · Autonomous University of Baja California Tijuana School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Endocrinology, Diabetes and Metabolism
- American Board of Internal Medicine - Internal Medicine
Medicaid work
$17,117 in 2024
Medicaid paid $17,117 for 598 billed services this clinician did in 2024, up to 77 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Clinic visit/encounter, all-inclusive | 133 | $16,558 |
| Short return visit (20+ min) | 17 | $406 |
| New patient visit (45+ min) | 154 | $152 |
| Glucose, blood by glucose monitoring device(s) cleared by the FDA specifically for home use | 93 | $2 |
| BODY MASS INDEX DOCD | 16 | $0 |
| Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD) | 56 | $0 |
| Most recent diastolic blood pressure less than 80 mm Hg (HTN, CKD, CAD) (DM) | 58 | $0 |
| Return visit (30+ min) | 55 | $0 |
| Bmi is documented above normal parameters and a follow-up plan is documented | 16 | $0 |
| 2024 | 598 | 9 | 77 | $17,117 |
Drugs they prescribed that Part D paid
$207,366
Pharmacies billed $207,366 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
227 generic and 233 brand-name prescriptions · $207,366 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Ozempic | 70 | $67,988 | $971 |
| Trulicity | 50 | $53,812 | $1,076 |
| Mounjaro | 16 | $16,644 | $1,040 |
| Farxiga | 18 | $11,989 | $666 |
| Tresiba Flextouch U-100 | 13 | $8,349 | $642 |
See all 10 drugs
| Ozempic | 70 | $67,988 | $971 |
| Trulicity | 50 | $53,812 | $1,076 |
| Mounjaro | 16 | $16,644 | $1,040 |
| Farxiga | 18 | $11,989 | $666 |
| Tresiba Flextouch U-100 | 13 | $8,349 | $642 |
| Levothyroxine | 52 | $612 | $12 |
| Methimazole | 18 | $397 | $22 |
| Metformin | 24 | $223 | $9 |
| Carvedilol | 11 | $76 | $7 |
| Dexamethasone | 14 | $8 | $1 |
Year by year
| 2024 | 483 | 126 | None | 48% | $207,366 |
| 2023 | 240 | 69 | None | None | $76,008 |
| 2022 | 129 | 19 | 0% (0) | None | $14,820 |
| 2021 | 34 | 12 | 0% (0) | None | $2,664 |
| 2020 | 14 | None | None | None | $1,127 |
| 2019 | 95 | 27 | None | 24% | $7,459 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 3 drugs
| Trulicity | 13 | $20,417 | $1,571 |
| Hydrocortisone | 31 | $1,400 | $45 |
| Levothyroxine | 37 | $668 | $18 |
2022: 3 drugs
| Hydrocortisone | 24 | $1,226 | $51 |
| Testosterone Cypionate | 15 | $510 | $34 |
| Levothyroxine | 37 | $411 | $11 |
Money from drug and device companies
$508 in 2025
| 2025 | 12 | 19 | None | $508 |
| 2024 | 6 | 10 | None | $205 |
| 2023 | 5 | 6 | None | $295 |
| 2021 | 3 | 3 | None | $280 |
| 2020 | 2 | 2 | None | $34 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Dexcom | Dexcom G7 Gss (161) | $154 | 3 payments
|
| Mannkind | Afrezza | $82 | 3 payments
|
| GlaxoSmithKline | Bexsero | $50 | 2 payments
|
| Lilly USA | Mounjaro | $37 | 2 payments
|
| Amgen | Evenity | $36 | 2 payments
|
| Exact Sciences | The Cologuard Plus Collection Kit | $30 | 1 payment
|
See all 19 published payments
| Amgen | Meals · 2025-12-11 | Evenity | $19 |
| Mannkind | Meals · 2025-12-11 | Afrezza | $16 |
| Shield Therapeutics | Meals · 2025-11-14 | Accrufer | $15 |
| Medtronic | Meals · 2025-10-20 | Minimed 780g | $19 |
| Xeris Pharmaceuticals | Meals · 2025-10-02 | Gvoke Hypopen | $17 |
| GlaxoSmithKline | Meals · 2025-09-11 | Bexsero | $27 |
| Dexcom | Meals · 2025-07-29 | Dexcom G7 Gss (161) | $122 |
| Dexcom | Meals · 2025-07-21 | Dexcom G6 Transmitter | $21 |
| Insulet | Meals · 2025-07-07 | Omnipod | $15 |
| Lilly USA | Meals · 2025-06-24 | Mounjaro | $14 |
| Abbott Laboratories | Meals · 2025-06-12 | Freestyle Libre 3 | $24 |
| Novo Nordisk | Meals · 2025-06-06 | Ozempic | $28 |
| Amgen | Meals · 2025-05-21 | Otezla | $17 |
| Mannkind | Education · 2025-05-08 | Afrezza | $43 |
| Mannkind | Meals · 2025-05-08 | Afrezza | $24 |
| Lilly USA | Meals · 2025-05-01 | Mounjaro | $23 |
| Exact Sciences | Meals · 2025-04-28 | The Cologuard Plus Collection Kit | $30 |
| Dexcom | Meals · 2025-03-21 | Dexcom G6 Transmitter | $10 |
| GlaxoSmithKline | Meals · 2025-03-17 | Bexsero | $22 |
See earlier years (2024, 2023, 2021, 2020)
2024: $205
| Novo Nordisk | Wegovy | $67 | 3 payments
|
| Corcept Therapeutics | Korlym | $44 | 2 payments
|
| Dexcom | Dexcom G6 Transmitter | $39 | 2 payments
|
| Medtronic | Minimed 780g | $22 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $17 | 1 payment
|
| Abbott Laboratories | Freestyle Libre 3 | $15 | 1 payment
|
2023: $295
| Tandem Diabetes Care | T:Slim X2 Insulin Pump With Control-Iq | $119 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $105 | 1 payment
|
| Dexcom | Dexcom G6 Transmitter | $34 | 2 payments
|
| Amgen | Evenity | $20 | 1 payment
|
| Horizon Therapeutics plc | Tepezza | $17 | 1 payment
|
2021: $280
| MannKind | Afrezza | $125 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $97 | 1 payment
|
| Abiomed | Impella | $58 | 1 payment
|
2020: $34
| Daiichi Sankyo | Enhertu | $18 | 1 payment
|
| Jazz Pharmaceuticals | Vyxeos | $16 | 1 payment
|
Professional record
- NPI
- 1164909735
- Licence
- CA A174340, NE 8186California A174340: Current · expires 2027-08-31
- Group
- Clinica Sierra Vista
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RE0101X (207RE0101X); Internal medicine (207R00000X)
- Mailing address
- 302 Fresno St Ste 101, Fresno, CA, 93706
- NPI first listed
- 2018-07-25
- NPI last updated
- 2024-10-02
- NPI record certified
- 2024-10-02
This is when the NPI record was last certified, not a medical board exam.